A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

Gallerani, Elisa; Bauer, Jean; Hess, Dagmar; Boehm, Steffen; Droege, C.; Jeckelmann, Sandrine; Miani, Monica; Herrmann, Richard; Marsoni, Silvia; Sperka, Sabine; Sessa, Cristiana

doi:10.3109/0284186x.2010.543697

Cited by 13 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there were some differences in DNA‐binding mode: (a) the aquation rate of JM118 was slower than that of cisplatin; (b) DNA bending from 1, 2‐GG intrastrand adduct of JM118 was lower than cisplatin; (c) DNA‐protein cross‐linking efficiency was higher for JM118 than cisplatin . Although satraplatin was effective against various cancer cells in vitro, satraplatin was mainly used in the treatment of prostate cancer in clinic, and was evaluated in a pivotal phase 3 clinical trial as second‐line therapy for patients with hormone refractory prostate cancer . The dose‐limiting satraplatin toxicities included nausea, vomiting, and myelosuppression, but renal and neurologic toxicities were seldom reported …”

Section: Platinum (Iv) Complex‐based Delivery Systemsmentioning

confidence: 99%

“…92,95,96 Although satraplatin was effective against various cancer cells in vitro, 92,[97][98][99] satraplatin was mainly used in the treatment of prostate cancer in clinic, and was evaluated in a pivotal phase 3 clinical trial as second-line therapy for patients with hormone refractory prostate cancer. 90,[100][101][102] The dose-limiting satraplatin toxicities included nausea, vomiting, and myelosuppression, but renal and neurologic toxicities were seldom reported. 69,103…”

Section: B Pt (Iv) Complexes In Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

Han

Sun

Wang

et al. 2015

Medicinal Research Reviews

View full text Add to dashboard Cite

Cisplatin and its platinum (Pt) (II) derivatives play a key role in the fight against various human cancers such as testicular, ovarian, head and neck, lung tumors. However, their application in clinic is limited due to dose- dependent toxicities and acquired drug resistances, which have prompted extensive research effort toward the development of more effective Pt (II) delivery strategies. The synthesis of Pt (IV) complex is one such an area of intense research fields, which involves their in vivo conversion into active Pt (II) molecules under the reducing intracellular environment, and has demonstrated encouraging preclinical and clinical outcomes. Compared with Pt (II) complexes, Pt (IV) complexes not only exhibit an increased stability and reduced side effects, but also facilitate the intravenous-to-oral switch in cancer chemotherapy. The overview briefly analyzes statuses of Pt (II) complex that are in clinical use, and then focuses on the development of Pt (IV) complexes. Finally, recent advances in Pt (IV) complexes in combination with nanocarriers are highlighted, addressing the shortcomings of Pt (IV) complexes, such as their instability in blood and irreversibly binding to plasma proteins and nonspecific distribution, and taking advantage of passive and active targeting effect to improve Pt (II) anticancer therapy.

show abstract

Section: Platinum (Iv) Complex‐based Delivery Systemsmentioning

confidence: 99%

Section: B Pt (Iv) Complexes In Clinical Trialsmentioning

confidence: 99%

Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

Han

Sun

Wang

et al. 2015

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Another trial evaluated the combination of oral V with another oral drug, capecitabine, showing a good profile of tolerability and similar toxicities, mainly nausea, diarrhea and neutropenia [20]. …”

Section: Discussionmentioning

confidence: 99%

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination with Oral Vinorelbine in Patients with Advanced Solid Malignancies

et al. 2013

Self Cite

View full text Add to dashboard Cite

Background: The broad spectrum of antitumor activity of the oral platinum satraplatin (S) and vinorelbine (V) were the rationale for performing a phase I trial to define the maximum tolerated (MTD) and the recommended (RD) dose in adult patients with advanced solid tumors. Patients and Methods: 4 dose levels (DLs) of S (mg/m²/day, days 1–5) and V (mg/m²/day, days 1, 8, 15, and 22) every 28 days were explored: S60/V60 on days 1, 8 and 15 only; S60/V60; S70/V60; and S80/V60. Subsequently, 3 further DLs were evaluated with V omitted on day 22: S70/V60, S80/V60, and S80/V80. Results: Treating 27 patients, the MTD was S80/V80 on days 1, 8, and 15, with 2 dose-limiting toxicities in 2 patients (nausea and vomiting grade (G) 3 with skipping of V on day 15, and neutropenia G4 with infection). The RD was S80/V60 on days 1, 8, and 15. The most frequent toxicities (any G) were nausea (70%), diarrhea (59%), anorexia (37%), vomiting (33%), asthenia (26%), constipation (26%), and paresthesia (18%). Partial responses were observed in 2 platinum-sensitive ovarian cancer patients and in 1 prostate cancer patient. Conclusion: The combination of S and V is tolerable at a DL of S80/V60 on days 1, 8, and 15; further evaluations in platinum- and V-sensitive tumor types would be of interest.

show abstract

“…Beispielsweise wurden Goldkomplexe zur Behandlung rheumatoider Arthritis entwickelt, Silberkomplexe als antimikrobische Wirkstoffe, Antimonkomplexe zur Behandlung von Leishmaniose, Vanadium(IV)-Komplexe als antivirale und antidiabetische Wirkstoffe, [2][3][4][5] Arsentrioxid (Trisenox) zur Behandlung akuter Promyelozytenleukämie [6] und metallaktiviertes Bleomycin zur Behandlung des Hodgkin-Lymphoms und von Hodenkrebs. [7] Auf Übergangsmetallen basierende Therapeutika, die sich zurzeit in klinischen Studien befinden, umfassen die dritte Generation von antitumoralen Platinkomplexen wie liposomales Cisplatin (Lipoplatin), Satraplatin und Picoplatin, [8,9] die antitumoralen Rutheniumkomplexe NAMI-A und KP-1019 [10] und den Antimalaria-Wirkstoff Ferroquin, ein Ferrocen-Chinolin-Konjugat. [11] Diese Beispiele führen die lange Geschichte therapeutischer Metallkomplexe fort und wecken die Hoffnung, dass das Gebiet der anorganischen Medizin sich in Zukunft energisch weiterentwickeln wird.…”

Section: Introductionunclassified

Bioaktive lumineszierende Übergangsmetallkomplexe für biomedizinische Anwendungen

Leung

et al. 2013

Angewandte Chemie

View full text Add to dashboard Cite

Die zufällige Entdeckung des krebshemmenden Wirkstoffs Cisplatin festigte in den 1960er Jahren die Stellung der medizinischen anorganischen Chemie. In der Folge kam es zu einem weitverbreiteten Einsatz lumineszierender Metallkomplexe in der Sensorik, in der biologischen Bildgebung und in organischen Leuchtdioden. Übergangsmetallkomplexe weisen viele Vorteile auf, aufgrund derer sie als Therapeutika und als Lumineszenzsonden für Biomoleküle geeignet sind. Daher ist die Entwicklung neuer lumineszierender Metallkomplexe wünschenswert, die über verschiedene Bindungsmodi mit DNA wechselwirken oder auf alternative Teile der zellulären Maschinerie, z. B. auf Proteine, abzielen, um effektivere Mittel zur Überwachung von Krankheitsverläufen zur Verfügung zu stellen. Hier präsentieren wir aktuelle Beispiele biologisch aktiver lumineszierender Metallkomplexe, die auf ein spezifisches Biomolekül abzielen und dieses sondieren, und diskutieren das Potenzial dieser Verbindungen zur Erforschung und Behandlung menschlicher Erkrankungen.

show abstract

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

Cited by 13 publications

References 15 publications

Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination with Oral Vinorelbine in Patients with Advanced Solid Malignancies

Bioaktive lumineszierende Übergangsmetallkomplexe für biomedizinische Anwendungen

Contact Info

Product

Resources

About